Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

FHTX

NASDAQ

Foghorn Therapeutics (FHTX)

5 USD 0.00% vs prior close
Foghorn Therapeutics Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Market cap
299.8M USD
P/E (TTM)
83.3
Revenue, year to Dec 2025
30.9M USD
EPS, diluted, year to Dec 2025
−1.18 USD
52-week range
3.50 USD – 6.68 USD
Avg volume
63.0K

as of Jul 17, 2026

Have Foghorn Therapeutics (FHTX) insiders bought or sold shares recently?

FHTX's newest Form 4 filing is dated 10 April 2026: none in the last 90 days.

Form 4

Have Foghorn Therapeutics (FHTX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
10 Apr 2026GOTTSCHALK ADRIANChief Executive OfficerGift118,416
09 Apr 2026GOTTSCHALK ADRIANChief Executive OfficerGift94,994

Which funds hold Foghorn Therapeutics (FHTX)?

6 of the 45 institutional funds we track reported a Foghorn Therapeutics position for the quarter ended 30 Sep 2026 — a combined 2.8M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Foghorn Therapeutics (FHTX)?
FundPositionSharesValueShares q/q
Renaissance TechnologiesHeld (±25%)432,3391.5M USD+14.4%
Citadel AdvisorsTrimmed106,479380K USD−33.0%
Point72 Asset ManagementNew position106,201379K USD
Millennium ManagementAdded82,236294K USD+53.7%
AQR Capital ManagementTrimmed37,375133K USD−43.6%
Two Sigma InvestmentsAdded16,62759K USD+33.6%

What has been filed or recorded for Foghorn Therapeutics (FHTX)?

The filings we hold for Foghorn Therapeutics, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 28 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Foghorn Therapeutics (FHTX)?
And
28 Oct 2026Fails to deliverShares failed to deliver2,177 shares4K USD notional · 0.004% of shares out
15 Oct 2026Fails to deliverShares failed to deliver1,514 shares3K USD notional · 0.003% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS 0.80 USDRevenue $84M
30 Sep 2026FinancialsTotal assets191.0M USDat period end
30 Sep 2026FinancialsTotal equity−14.1M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.10 USDRevenue $16M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.29 USDRevenue $3M
31 Dec 2025Annual reportFY 2025 reportedEPS −1.18 USDRevenue $31M
31 Dec 2025FinancialsRevenue30.9M USDfiscal year
31 Dec 2025FinancialsNet income−74.3M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.18 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.25 USDRevenue $8M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.28 USDRevenue $8M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.30 USDRevenue $6M
31 Dec 2024Annual reportFY 2024 reportedEPS −1.58 USDRevenue $23M

What do people ask about Foghorn Therapeutics (FHTX)?

From live data
What is Foghorn Therapeutics’ market cap?299.8M

Foghorn Therapeutics is worth 299.8M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

What is Foghorn Therapeutics’ P/E ratio?83.3

Foghorn Therapeutics has a price-to-earnings ratio of 83.3, as of 17 Jul 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.

What is Foghorn Therapeutics’ revenue?30.9M

Foghorn Therapeutics reported revenue of 30.9M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Foghorn Therapeutics insiders bought or sold shares recently?

No Foghorn Therapeutics insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 10 Apr 2026 (SEC Form 4). See Insiders

Which funds own Foghorn Therapeutics?6 of 45

6 of the 45 funds we track reported a Foghorn Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, Citadel Advisors and Point72 Asset Management. See Funds

When did Foghorn Therapeutics last report earnings?0.80

Foghorn Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.80 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words